Loading articles...
Patients with chronic dermatologic conditions face a delicate balance between disease control and infection risk when using JAK inhibitors and biologics. This meta-analysis prompts clinicians to carefully evaluate individual patient risk profiles before ini...
Dermatology patients on advanced immunomodulatory therapies face an elevated risk of infection, demanding vigilant monitoring. This meta-analysis prompts a crucial reevaluation of comparative safety profiles between JAK inhibitors and biologics in managing ...
The discovery of two new Mycobacterium species, *Mycobacterium camsae* and *Mycobacterium pumcae*, isolated from human skin infections, highlights the ongoing evolution of our understanding of microbial diversity. Clinicians should consider that conventiona...